Sources: the FDA rejected Neuralink's clinical trial application, citing dozens of issues to fix before human testing, like the device's removal and its battery
Musk has said his brain implant company, Neuralink, will make the paralyzed walk, the blind see and eventually turn people into cyborgs.
Context & Ripple Effects
The rejection lands after a string of public deadlines: back in 2019 Neuralink had $158M in funding and targeted human testing by mid-2020, and Musk repeated in December 2022 that trials would begin within about six months pending FDA approval. Reuters now reports the regulator instead rejected the application outright, flagging dozens of unresolved issues.
The arc matters because the two named blockers — device removal and the battery — are exactly the kind of long-term implantation questions regulators weigh for a chip meant to stay in the skull indefinitely. The story doesn't end here: within three months Neuralink announced first-in-human FDA approval, and by September it was enrolling paralysis patients for a study expected to run about six years with fewer than ten people.
First-order effects
- Neuralink cannot begin human testing until it resolves the FDA's dozens of listed issues, making the removal and battery problems the gating items for Musk's paralysis and vision ambitions.
- The rejection punctures the December timeline of trials starting within six months, forcing Neuralink to rework the application rather than recruit patients.
Second-order effects
- The fix list effectively becomes the template for later sign-offs: when FDA approved a second implant, sources said it had signed off on proposed fixes like embedding the wires deeper into the brain — evidence the rejection's demands were absorbed into the design.
- Rival BCI developers get breathing room on the clinical calendar, though the related coverage notes Neuralink still commands outsized media attention relative to competitors even amid hype worries.
Third-order effects
- If the pattern holds, FDA review cadence — not founder timelines — sets the pace for US brain-implant development, and any company seeking high-volume production plans, such as Neuralink's stated 2026 manufacturing push, will need this regulatory loop closed first.
The trend: Implantable brain-computer interfaces are advancing in the US on the FDA's clock, with each rejection-and-revision cycle converting startup timelines into regulator-approved milestones.